Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Accumulated Depreciation & Amortization (2020 - 2025)

Cytek Biosciences' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 5.09% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, up 5.09%, while the annual FY2025 figure was $7.6 million, 5.09% up from the prior year.
  • Accumulated Depreciation & Amortization reached $7.6 million in Q4 2025 per CTKB's latest filing, up from $5.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $7.6 million in Q4 2025 to a low of $1.0 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.3 million, with a median of $2.5 million recorded in 2022.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 155.17% in 2023 against a maximum downside of 54.54% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.2 million in 2021, then soared by 100.64% to $2.5 million in 2022, then surged by 142.7% to $6.0 million in 2023, then rose by 19.25% to $7.2 million in 2024, then increased by 5.09% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Accumulated Depreciation & Amortization are $7.6 million (Q4 2025), $5.7 million (Q3 2025), and $3.8 million (Q2 2025).